CAS：1491917-83-9

国际站：Sacituzumab govitecan​

牌：MedChemExpress (MCE)

存储条件：Please store the product under the recommended conditions in the Certificate of Analysis.

生物活性：Sacituzumab govitecan (IMMU-132) 是一种抗体-药物偶联物 (ADC)，靶向 Trop-2 以递送 SN-38。 Sacituzumab govitecan 具有抗癌活性^[1]。

体内：Sacituzumab govitecan (IMMU-132)（17.5 mg/kg；每周两次，持续 4 周）对携带人胃癌异种移植物的小鼠产生显着的抗肿瘤作用^[1]。

参考文献：

[1]. Cardillo TM, et al. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjug Chem. 2015 May 20;26(5):919-31.

[2]. Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) [published correction appears in Oncotarget. 2020 Mar 10;11(10):942]. Oncotarget. 2015;6(26):22496-22512.

转载本文请联系原作者获取授权，同时请注明本文来自仇伟伟科学网博客。

链接地址：https://wap.sciencenet.cn/blog-3506747-1427293.html?mobile=1

收藏

分享